CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 471 enrolled
Drug / intervention
JNJ-73763989 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03982186
NCT03982186Phase 2Completed
CompareCT.gov

A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

Janssen Sciences Ireland UC·interventional·Posted Jun 11, 2019·Updated Feb 4, 2025

In Brief

A Phase 2 clinical trial evaluating JNJ-73763989, Placebo for JNJ-73763989, and 3 other interventions for Hepatitis B, Chronic. Completed, enrolled 471 participants across 108 sites in 19 countries.

Detailed Summary

The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA (with and without JNJ-56136379) and of JNJ-56136379+NA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesBelgium, Brazil, Canada, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Malaysia, Poland, Russia, South Korea, Spain, Thailand, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 11, 2019
Enrollment StartAug 1, 2019
Primary CompletionMar 29, 2021
Study CompletionApr 26, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.1 years ago

Interventions

JNJ-73763989drug

JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.

Placebo for JNJ-73763989drug

Placebo for JNJ-73763989 will be administered as subcutaneous injection.

JNJ-56136379drug

JNJ-56136379 tablets will be administered orally.

Placebo for JNJ-56136379drug

Placebo for JNJ-56136379 tablets will be administered orally.

Nucleos(t)ide Analog (NA)drug

NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.